To isolate pDCs, cDCs, and monocytes, human PBMCs were labeled with Alexa 647 anti-human CD11c (301620, clone 3.9, BioLegend), anti-human HLA-DR (Class III) PE-Texas conjugate (MHLDR17, Life Technology), BV421 anti-human CD14 (325627, clone HCD14, BioLegend), PE-Cy7 anti-human CD123 (560826, clone 7G3, BD Biosciences), APC-Fire 750 anti-human CD8a (301065, clone RPA-T8, BioLegend), APC-Fire 750 anti-human CD20 (302357, clone 2H7, BioLegend), APC-H7 anti-human CD3 (560275, clone SK7, BD Pharmingen) and Live/Dead Fixable Aqua Dead Cell Stain Kit (L34966, Invitrogen). Labeled cells were fixed with 4% PFA in PBS for 5 min, then cell marker expression was analyzed and cells were isolated with BD FACSAria II (BD Biosciences). The gating strategy is shown in Supplementary Figure S4 .
To isolate CD4+ T, CD8+ T, NK, and B cells, human PBMCs were labeled with APC-H7 anti-human CD3 (560275, BD Bioscience), PE-Cy7 anti-human CD4 (317413, Biolegend), PE anti-human CD56 (355503, Biolegend), FITC anti-human CD8 (300905, Biolegend), APC anti-human CD19 (302211, Biolegend), and Live/Dead Fixable Aqua Dead Cell Stain Kit (L34966, Invitrogen). Labeled cells were fixed with 4% PFA in PBS for 5 min, then expression markers were analyzed and cells were isolated with BD FACSAria II (BD Biosciences). The gating strategy is shown inSupplementary Figure S4 .
To isolate CD4+ T, CD8+ T, NK, and B cells, human PBMCs were labeled with APC-H7 anti-human CD3 (560275, BD Bioscience), PE-Cy7 anti-human CD4 (317413, Biolegend), PE anti-human CD56 (355503, Biolegend), FITC anti-human CD8 (300905, Biolegend), APC anti-human CD19 (302211, Biolegend), and Live/Dead Fixable Aqua Dead Cell Stain Kit (L34966, Invitrogen). Labeled cells were fixed with 4% PFA in PBS for 5 min, then expression markers were analyzed and cells were isolated with BD FACSAria II (BD Biosciences). The gating strategy is shown in